Literature DB >> 2553163

Recombinant human interleukin-3 and granulocyte-macrophage colony-stimulating factor show common biological effects and binding characteristics on human monocytes.

M J Elliott1, M A Vadas, J M Eglinton, L S Park, L B To, L G Cleland, S C Clark, A F Lopez.   

Abstract

Two human hemopoietic growth factors involved in monocytopoiesis, interleukin-3 (IL-3) and granulocyte-macrophage colony-stimulating factor (GM-CSF) were studied for their ability to stimulate blood monocytes and to bind to the monocyte membrane. Both cytokines maintained monocyte/macrophage numbers during long-term culture and increased cell size as compared with controls. Effects on cell numbers were present at low cytokine concentrations (6 to 20 pmol/L), whereas enhanced 3H-thymidine incorporation was observed only at higher concentrations (greater than or equal to 60 pmol/L). Autoradiographic studies showed only 1% to 3% of stimulated monocytes with nuclear grains. These results suggest that the primary mechanism for IL-3 and GM-CSF-induced maintenance of monocyte/macrophage numbers in humans is through an effect on cell survival. Surface receptors for both IL-3 and GM-CSF were studied by using 125I-labeled recombinant human (rh) cytokines and performing Scatchard analyses. Both cytokines showed curvilinear Scatchard plots, and computer analyses favored a two-site binding model. High-affinity binding data for 125I rhIL-3 (Kd 7.7 to 38.2 pmol/L; receptor number/cell 95 to 580) and for 125I rhGM-CSF (Kd 4.7 to 38.9 pmol/L; receptor number/cell 8 to 67) show similar binding affinities for the two cytokines but a lower receptor number/cell for 125I rhGM-CSF. Low-affinity binding characteristics for 125I rhIL-3 (Kd 513 to 939 pmol/L; receptor number/cell 179 to 5,274) and for 125I rhGM-CSF (Kd 576 to 1,120 pmol/L; receptor number/cell 130 to 657) show a similar pattern for the two cytokines. Specificity of 125I rhIL-3 and 125I rhGM-CSF binding to monocytes was established by the ability of the homologous cytokine to inhibit binding and the inability of a range of other cytokines to compete at 100-fold excess molar concentration. It is important, however, that binding of 125I rhIL-3 was partially inhibited by rhGM-CSF and that rhIL-3 partially inhibited binding of 125I rhGM-CSF to the monocyte membrane under conditions shown to prevent receptor internalization. The degree of inhibition varied between 25% and 80% in different experiments, and quantitative inhibition experiments showed that 1,000-fold excess concentrations of competitor failed to inhibit binding of the heterologous ligand completely. These results demonstrate that human IL-3 and GM-CSF have similar effects on growth and survival of human monocytes in vitro and suggest that these and other common biological effects may be mediated either through a common receptor or through distinct receptors associated on the monocyte membrane.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2553163

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  24 in total

1.  Enhanced hematopoietic activity of a human granulocyte/macrophage colony-stimulating factor-interleukin 3 fusion protein.

Authors:  B M Curtis; D E Williams; H E Broxmeyer; J Dunn; T Farrah; E Jeffery; W Clevenger; P deRoos; U Martin; D Friend
Journal:  Proc Natl Acad Sci U S A       Date:  1991-07-01       Impact factor: 11.205

2.  Lymphocytes stimulate expression of 5-lipoxygenase and its activating protein in monocytes in vitro via granulocyte macrophage colony-stimulating factor and interleukin 3.

Authors:  W L Ring; C A Riddick; J R Baker; D A Munafo; T D Bigby
Journal:  J Clin Invest       Date:  1996-03-01       Impact factor: 14.808

3.  The role of granulocyte colony-stimulating factor in the neutrophilia observed in the fetal inflammatory response syndrome.

Authors:  Tinnakorn Chaiworapongsa; Roberto Romero; Stanley M Berry; Sonia S Hassan; Bo Hyun Yoon; Samuel Edwin; Moshe Mazor
Journal:  J Perinat Med       Date:  2011-07-30       Impact factor: 1.901

4.  A functional isoform of the human granulocyte/macrophage colony-stimulating factor receptor has an unusual cytoplasmic domain.

Authors:  K E Crosier; G G Wong; B Mathey-Prevot; D G Nathan; C A Sieff
Journal:  Proc Natl Acad Sci U S A       Date:  1991-09-01       Impact factor: 11.205

5.  Regulation by interleukin-3 of human monocyte pro-inflammatory mediators. Similarities with granulocyte-macrophage colony-stimulating factor.

Authors:  P H Hart; G A Whitty; D R Burgess; J A Hamilton
Journal:  Immunology       Date:  1990-09       Impact factor: 7.397

6.  Human interleukin-3 (IL-3) induces disulfide-linked IL-3 receptor alpha- and beta-chain heterodimerization, which is required for receptor activation but not high-affinity binding.

Authors:  F C Stomski; Q Sun; C J Bagley; J Woodcock; G Goodall; R K Andrews; M C Berndt; A F Lopez
Journal:  Mol Cell Biol       Date:  1996-06       Impact factor: 4.272

7.  Active DNA demethylation in human postmitotic cells correlates with activating histone modifications, but not transcription levels.

Authors:  Maja Klug; Sven Heinz; Claudia Gebhard; Lucia Schwarzfischer; Stefan W Krause; Reinhard Andreesen; Michael Rehli
Journal:  Genome Biol       Date:  2010-06-18       Impact factor: 13.583

8.  Cloning of the low-affinity murine granulocyte-macrophage colony-stimulating factor receptor and reconstitution of a high-affinity receptor complex.

Authors:  L S Park; U Martin; R Sorensen; S Luhr; P J Morrissey; D Cosman; A Larsen
Journal:  Proc Natl Acad Sci U S A       Date:  1992-05-15       Impact factor: 11.205

9.  A human interleukin 3 analog with increased biological and binding activities.

Authors:  A F Lopez; M F Shannon; S Barry; J A Phillips; B Cambareri; M Dottore; P Simmons; M A Vadas
Journal:  Proc Natl Acad Sci U S A       Date:  1992-12-15       Impact factor: 11.205

10.  The alpha subunit of the human granulocyte-macrophage colony-stimulating factor receptor signals for glucose transport via a phosphorylation-independent pathway.

Authors:  D X Ding; C I Rivas; M L Heaney; M A Raines; J C Vera; D W Golde
Journal:  Proc Natl Acad Sci U S A       Date:  1994-03-29       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.